The number of biopharma and biotech companies developing and launching new therapies is continuing to rise with emerging biopharma remaining a strong source of innovation. At the same time, more barriers to success are emerging with requirements for increasingly complex clinical trials, continuous regulatory changes, evolving payer conditions, and more restrictive access to HCPs. It’s..

The number of biopharma and biotech companies developing and launching new therapies is continuing to rise with emerging biopharma remaining a strong source of innovation. At the same time, more barriers to success are emerging with requirements for increasingly complex clinical trials, continuous regulatory changes, evolving payer conditions, and more restrictive access to HCPs. It’s..

The number of biopharma and biotech companies developing and launching new therapies is continuing to rise with emerging biopharma remaining a strong source of innovation. At the same time, more barriers to success are emerging with requirements for increasingly complex clinical trials, continuous regulatory changes, evolving payer conditions, and more restrictive access to HCPs. It’s..